BioCentury
ARTICLE | Product Development

Seeking structural endpoints for OA

Companies turn to imaging-based endpoints for first wave of disease-modifying OA therapies

January 10, 2020 11:09 PM UTC
Updated on Jan 10, 2020 at 11:16 PM UTC

As the first disease-modifying therapies for osteoarthritis enter late-stage development, companies are testing new endpoints that can capture effects on joint structure instead of relying on traditional pain-related readouts. Most are converging on MRI imaging for its superior sensitivity to X-ray.

Readouts this year will help determine whether either method can demonstrate a slowing of already slow disease progression in osteoarthritis (OA) patients...